Long-term follow up after coronary sirolimus drug-eluting stent implantation for cardiac transplant arteriopathy

Journal of Invasive Cardiology

Volumn 18, Issue 4, 2006, Pages 184-185

  Yoon, Edward J ^a   Haeusslein, Ernest ^a   Brent, Bruce ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; RAPAMYCIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DISEASE; ARTICLE; CASE REPORT; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FOLLOW UP; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LONG TERM CARE; LUNG TOXICITY; MALE; RESTENOSIS; RISK REDUCTION; THROMBOCYTOPENIA; VASCULAR PATENCY; CORONARY ARTERY ATHEROSCLEROSIS; HEART INFARCTION; MIDDLE AGED; RADIOGRAPHY; STENT; TREATMENT OUTCOME;

CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 33745095057     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Julius BK, Attenhofer JCH, Sutsch G, et al. Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. Transplantation 2000;69:847-854.
2. Constanzo M, Naftel D, Pritzker M, et al. Heart transplant coronary artery disease detected by coronary angiography: A multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1998;17:744-753.
3. Edelman ER, Danenberg HD. Rapamycin for cardiac transplant rejection and vasculopathy. One stone, two birds? Circulation 2003;108:6.
4. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003;107:93-97.
5. Halle AA, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1995;26:120-128.
6. Benza RL, Zoghbi GJ, Tallaj J. Palliation of allograft vasculopathy with transluminal angioplasty: A decade of experience. J Am Coll Cardiol 2004;43:1973-1981.
7. Jain SP, Ramee SR, White CJ, et al. Coronary stenting in cardiac allograft vasculopathy. J Am Coll Cardiol 1998;32:1636-1640.
8. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004;110:2694-2700.
9. Mancini M, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53.
10. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858.
11. Tomai F, Gagliardi G, Proietti I. Sirolimus-eluting stent implantation in a heart transplant recipient. Ital Heart J 2004;5:408-409.
12. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Eng J Med 2002;346:1773-1780.
13. FDA Center for Devices and Radiological Health website. "CYPHER Sirolimus-eluting coronary stent on RAPTOR over-the-wire delivery system."
14. Pham PT, Pham PC, Danovitch, GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004;77:1215-1220.